DRI Capital to float pharma royalties fund in London

By Aidan Gregory
12 Feb 2020

Canada’s DRI Capital is preparing to list a new fund on the London Stock Exchange focused on investing in pharmaceuticals royalties.

In an intention to float document, DRI Healthcare, as the new closed end fund will be known, said it would raise $350m by selling new shares to institutional investors. Jefferies is global co-ordinator, Numis Securities is bookrunner and sponsor.

The proceeds of the transaction will be used to ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.